Ulixertinib + Ruxolitinib combination (ERK1/2 + JAK inhibition in myelofibrosis)
Current understanding
To be populated as evidence accumulates.
Evidence log
- April 28, — Biomed Valley Discoveries Phase 1/2 Trial: Ulixertinib + Ruxolitinib for Myelofibrosis: Biomed Valley Discoveries Phase 1/2 trial (trial-early) initiated combining ulixertinib (selective ERK1/2 inhibitor) with ruxolitinib (JAK1/2 inhibitor) in myelofibrosis — first clinical test of dual ERK/MAPK + JAK pathway blockade, rationalized by MAPK reactivation as a JAK-inhibition escape mechanism; no efficacy or safety data yet. (novelty: 4)
Open questions
Related
Contributing findings
Biomed Valley Discoveries Phase 1/2 Trial: Ulixertinib + Ruxolitinib for Myelofibrosis
April 28, 2025
novelty 4
per-area 4
introduces